The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Detection of EGFR mutations with mutation-specific antibodies in primary lesions of non-small cell lung cancer.
X. Zhang
No relevant relationships to disclose
L. Yin
Employment or Leadership Position - AstraZeneca
X. Yang
No relevant relationships to disclose
J. Yang
No relevant relationships to disclose
Q. Zhou
No relevant relationships to disclose
J. Xu
Employment or Leadership Position - AstraZeneca
Z. Xie
No relevant relationships to disclose
S. An
No relevant relationships to disclose
S. Chen
No relevant relationships to disclose
R. Wang
Employment or Leadership Position - AstraZeneca
G. Zhu
Employment or Leadership Position - AstraZeneca
Y. Gu
Employment or Leadership Position - AstraZeneca
X. Zhang
Employment or Leadership Position - AstraZeneca
Y. L. Wu
No relevant relationships to disclose